Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLOVAGE vs EUTHROID-0.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.
Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
Colonoscopy preparation,Bowel cleansing prior to colorectal surgery
Replacement therapy in hypothyroidism (primary, secondary, tertiary),Suppression of TSH in thyroid cancer (off-label),Treatment of euthyroid goiter (off-label)
4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.
Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.
Not applicable (non-absorbed, gut lavage); systemic absorption minimal
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal and hepatic function; clinically, steady-state is reached within 24-36 hours, and dosing interval adjustments may be needed in renal or hepatic impairment.
Polyethylene glycol 3350 is not absorbed systemically; no hepatic metabolism.
Levothyroxine (T4) is deiodinated to liothyronine (T3) primarily by type 1 and type 2 deiodinases in liver, kidney, and other tissues. T3 and T4 are also metabolized via glucuronidation and sulfation. Hepatic enzymes: UGT1A1, UGT1A3, SULT1A1.
Primarily fecal as unabsorbed drug; negligible renal excretion (<5%)
Renal (approx. 20-40% as unchanged drug, primarily via glomerular filtration and tubular secretion); biliary/fecal (approx. 60-80% as metabolites and unchanged drug, with enterohepatic recirculation).
Not applicable (minimal systemic absorption)
Approximately 99% bound to serum proteins, primarily thyroxine-binding globulin (TBG), with lesser binding to transthyretin and albumin.
Not applicable (limited to gastrointestinal tract)
Apparent volume of distribution is approximately 0.10-0.15 L/kg, indicating distribution primarily into extracellular fluid and highly protein-bound; small Vd reflects minimal tissue binding under steady-state conditions.
Oral: <0.3% systemically absorbed
Oral bioavailability: 100% (tablets), as EUTHROID-0.5 is a combination product with synthetic T4 (levothyroxine) and T3 (liothyronine); T4 absorption is ~80% (fasting, taken with water), while T3 is nearly completely absorbed; overall bioavailability considered complete when taken as directed.
Contraindicated in GFR <30 m L/min/1.73 m²; for GFR 30-60 m L/min/1.73 m², use with caution due to risk of electrolyte imbalance, no dose adjustment recommended.
No dose adjustment required for GFR >30 m L/min; for GFR <30 m L/min, consider reducing dose by 25-50% and monitor TSH.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential fluid and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50% and monitor TSH.
Not indicated for patients under 18 years of age; no established weight-based dosing.
Oral: 0.5-1 grain (30-60 mg) per 70 kg body weight once daily; for children <70 kg, use 0.5 grains (30 mg) once daily adjusted to TSH levels.
No specific dose adjustment, but monitor for electrolyte disturbances, dehydration, and aspiration risk; consider split-dose regimen or lower volume if tolerated.
Initiate at 0.5 grains (30 mg) orally once daily; titrate slowly with 0.5 grain increments every 4-6 weeks; monitor for tachyarrhythmias and osteoporosis.
Risk of fluid and electrolyte abnormalities (e.g., hyponatremia, seizures) in patients with impaired renal function, dehydration, or those taking medications affecting electrolytes.
No FDA boxed warning.
Monitor for fluid and electrolyte disturbances, especially in elderly, debilitated, or renal impaired patients. Use with caution in patients with gastrointestinal obstruction, ileus, or severe colitis.
Cardiovascular effects: angina, arrhythmias, heart failure. Thyrotoxicosis: excessive doses may cause symptoms of hyperthyroidism. Bone mineral density reduction with long-term overreplacement. Adrenal insufficiency: may precipitate crisis in untreated patients. Diabetes: insulin/oral hypoglycemic requirements may increase. Myxedema coma: rapid correction can be fatal.
Gastrointestinal obstruction, ileus, gastric retention, bowel perforation, toxic colitis or megacolon, hypersensitivity to any component.
Hypersensitivity to active ingredients or excipients. Untreated adrenal insufficiency. Thyrotoxicosis (hyperthyroidism). Acute myocardial infarction. Uncontrolled cardiovascular disease.
Only clear liquids (e.g., water, clear broth, black coffee/tea, clear juices) are allowed during bowel preparation. Avoid all solid foods, dairy products, red or purple liquids, and alcohol. Do not consume any food containing pulp or seeds.
Avoid taking with high-fiber foods, soy, or calcium supplements; separate by at least 4 hours.
Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.
EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoid, as untreated hypothyroidism is linked to congenital anomalies and neurodevelopmental deficits. No evidence of fetal harm from levothyroxine at therapeutic doses. Second and third trimester: transfers minimal amounts across placenta, but adequate maternal levels are essential for fetal neurodevelopment. Risk of fetal goiter if mother is overtreated (TSH suppression).
Due to lack of systemic absorption, excretion into breast milk is negligible. Colovage is considered compatible with breastfeeding. M/P ratio: not applicable.
Levothyroxine is excreted into breast milk in minimal amounts, but no adverse effects in nursing infants have been reported. The milk-to-plasma (M/P) ratio is approximately 0.5 (range 0.4-0.6). Breastfeeding is considered safe while on levothyroxine therapy. Monitor infant thyroid function if high doses are used.
No dose adjustment necessary; pharmacokinetics unchanged as drug is not absorbed.
Pregnancy increases levothyroxine requirements in many women with hypothyroidism. Dose often increases by 30-50% starting at 4-6 weeks gestation. Monitor TSH and free T4 every 4-6 weeks and adjust dose accordingly to maintain euthyroid state. Postpartum, dose usually returns to prepregnancy levels.
COLOVAGE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is a high-volume colon cleansing preparation. Ensure adequate hydration before, during, and after use. Monitor for electrolyte disturbances in patients with renal impairment or those taking diuretics. Split-dose regimen improves tolerance and cleansing quality. Avoid use in patients with gastrointestinal obstruction, perforation, or toxic megacolon.
Euthroid-0.5 contains liothyronine (T3). Monitor for signs of thyrotoxicosis due to rapid onset. T3 has a shorter half-life than levothyroxine; consider twice-daily dosing. Use with caution in elderly and patients with cardiac disease.
Follow the split-dose regimen exactly as prescribed to achieve optimal bowel cleansing.,Drink additional clear liquids as directed to prevent dehydration.,Do not eat any solid food while taking the preparation; only clear liquids are allowed.,Expect frequent, watery stools; stay near a restroom.,Contact your doctor if you experience severe abdominal pain, vomiting, or signs of dehydration.
Take exactly as prescribed, usually once daily.,Do not stop abruptly without consulting your doctor.,Report symptoms of hyperthyroidism: palpitations, tremor, anxiety, heat intolerance.,Store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLOVAGE vs EUTHROID-0.5, answered by our medical review team.
COLOVAGE is a Osmotic Laxative that works by COLOVAGE is a bowel cleansing preparation containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative, causing fluid retention in the colon to stimulate bowel evacuation.. EUTHROID-0.5 is a Thyroid Hormone Replacement that works by Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLOVAGE and EUTHROID-0.5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLOVAGE is: 4 liters of PEG-3350 electrolyte solution orally as a single dose for colon cleansing prior to colonoscopy; alternatively, 2 liters with ascorbic acid regimen.. The standard adult dose of EUTHROID-0.5 is: Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLOVAGE and EUTHROID-0.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLOVAGE is classified as Category C. Colovage (polyethylene glycol 3350) is not absorbed systemically; no teratogenic risk anticipated in any trimester. No fetal risks reported with oral use.. EUTHROID-0.5 is classified as Category C. EUTHROID-0.5 contains levothyroxine. Thyroid hormones are not associated with major teratogenic risk. In the first trimester, maternal hypothyroidism (treated) is important to avoi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.